Third dose Covid vaccine, Pfizer: “In children 5-11 years old it strengthens anti-Omicron defenses”

New data on Pfizer / BioNTech’s anti-Covid vaccine in children aged 5-11 show that administering a third dose (10 micrograms dosage) about 6 months after the second increases the protection of even the smallest. In particular – summarize the two companies in a note – the results of a sub-analysis conducted on the sera of 30 children participating in the phase 2/3 study on the age group 5-11 indicate, with a third dose of vaccine compared to two, a 36-fold increase in the titers of Sars-CoV-2 Omicron variant neutralizing antibodies. In addition, in the phase 2/3 clinical trial of 140 children, a third dose of the vaccine increased neutralizing antibodies against the parent strain of Sars-CoV-2 by 6 times. The injection proved to be well tolerated, with no new safety alerts emerging. The American Pfizer and its German partner BioNTech intend to submit a request for emergency use authorization to the US drug agency FDA in the coming days ( Eua) for a booster vaccine dose in children aged 5-11 years. The companies also plan to share this data with the European Medicines Agency Ema and other regulatory bodies around the world as soon as possible.